Mechanisms that might explain the cognitive benefits of Mannatech’s
glyconutrients and other polysaccharides are explored
COPPELL, Texas--(BUSINESS WIRE)--Mar. 27, 2012--
Mannatech,
Incorporated (NASDAQ: MTEX),
the leading innovator and provider of nutritional supplements based on Real
Food Technology® solutions, recently announced
the publication of a comprehensive literature review reporting the
effects of polysaccharides on brain function. Dr. Erika Nelson, a
neuroscientist, and her colleagues reviewed controlled studies assessing
various roles of exogenous saccharide compounds and polysaccharide-rich
extracts on brain function, with a significant focus on benefits derived
from oral intake. Her review includes a discussion of five randomized,
double-blind, placebo-controlled clinical trials that indicate that
Ambrotose® complex, a Mannatech product, positively impacts
well-being, memory, cognitive function and mood in healthy adults.*
Numerous preclinical studies were also identified that indicate various
polysaccharides can modify behavior, enhance synaptic plasticity and
provide neuroprotective effects.
“Mannatech has consistently demonstrated a strong commitment to
evaluating the impact of oral polysaccharide compounds on human health,”
said Dr. Robert Sinnott, CEO and Chief Science Officer at Mannatech. “In
2010, we published a review—which has been of great interest to the
scientific community—which consolidated the extant literature reporting
significant impacts of oral polysaccharides on immune function. Today,
we are once again pleased to offer an important consolidation of the
literature investigating the impact of oral polysaccharides on brain
health and function. This literature review both clarifies the current
state of the science in this area and suggests appropriate avenues for
future research that will help us better understand the benefits of
these important compounds.”
Dr. Nelson earned her BS in Genetics from the University of Kansas in
Lawrence and went on to obtain her PhD in Neuroscience at the University
of Texas Southwestern Medical Center in Dallas. She has published a
number of papers on neurodevelopmental disorders and brain epigenetics.
A candidate for a Masters of Business Administration at the University
of Texas at Dallas, Dr. Nelson is also a consultant for Mannatech.
Co-authors of the review include Dr. Robert Sinnott; Dr. Talitha Best, a
scientist with dual appointments at the University of South Australia,
Adelaide, and Swinburne University of Technology, Victoria, Australia;
and Jane Ramberg, Director of Product Substantiation at Mannatech.
Individuals interested in Mannatech’s products or exploring its business
opportunity are encouraged to learn more at Mannatech.com.
About Mannatech
Mannatech, Incorporated, develops high-quality health, weight and
fitness, and skin care products that are based on the solid foundation
of nutritional science and development standards. Mannatech is dedicated
to its platform of Social Entrepreneurship based on the foundation of
promoting, aiding and optimizing nutrition where it is needed most
around the world. Mannatech’s proprietary products are available through
independent sales Associates around the globe including the United
States, Canada, South Africa, Australia, New Zealand, Austria, Denmark,
Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan,
Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech
Republic, the Republic of Korea, Mexico and Namibia. For more
information, visit Mannatech.com.
Please note: This release contains “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as amended,
and the Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally can be identified by use of phrases
or terminology such as “believe,” “intend” or other similar words or the
negative of such terminology. Similarly, descriptions of Mannatech’s
objectives, strategies, plans, goals or targets contained herein are
also considered forward-looking statements. Mannatech believes this
release should be read in conjunction with all of its filings with the
United States Securities and Exchange Commission and cautions its
readers that these forward-looking statements are subject to certain
events, risks, uncertainties and other factors. Some of these factors
include, among others, Mannatech’s inability to attract and retain
Associates and Members, increases in competition, litigation, regulatory
changes and its planned growth into new international markets. Although
Mannatech believes that the expectations, statements and assumptions
reflected in these forward-looking statements are reasonable, it
cautions readers to always consider all of the risk factors and any
other cautionary statements carefully in evaluating each forward-looking
statement in this release, as well as those set forth in its latest
Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other
filings filed with the United States Securities and Exchange Commission,
including its current reports on Form 8-K. All of the forward-looking
statements contained herein speak only as of the date of this release.
*This statement has not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat, cure or
prevent any disease.
Current link to publication: http://www.ingentaconnect.com/content/maney/nns/pre-prints/1476830512Y.0000000004
Source: Mannatech, Incorporated
Mannatech, Incorporated
Brett Duncan, 972-471-7367
bduncan@mannatech.com